Document:

EX-10.44

 [Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been
omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.] 

Exhibit 10.44 
 CLINICAL
TRIAL PARTICIPATION AGREEMENT 
 THIS CLINICAL TRIAL PARTICIPATION AGREEMENT (the “Agreement”) is entered into
as of this 17 December, 2020 (the “Effective Date”) by and between QUANTUM LEAP HEALTH CARE COLLABORATIVE, a California nonprofit public benefit corporation, located at 3450 California Street, 2nd Floor, San Francisco, CA
94118, (“QLHC”), and NeuroRx, Inc, located at 1201 North Market St. Wilmington, DE 19801 (“Company”). QLHC and Company may each be referenced herein individually as a “Party” and together as
the “Parties.” 
 WHEREAS, QLHC is the sponsor of a clinical trial (the “Study”) in accordance with
a clinical research protocol entitled “I-SPY COVID-19 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis): An Adaptive COVID-19 Trial Design in the Setting of Critically Ill
Patients” (the “Protocol”), as such Protocol may be amended from time to time; 
 WHEREAS, QLHC has authorized,
and may, in the future, authorize one or more designees (each, a “CRO”) to act on behalf of QLHC in connection with certain of QLHC’s responsibilities related to the administration and performance of the Study. 

WHEREAS, QLHC and/or CRO will enter into clinical trial agreements with Institutions (as defined below) with expertise in and
facilities suitable for conducting the Study in accordance with the Protocol, such clinical trial agreement, and all applicable federal, state and local laws, rules, regulations and guidelines. 

WHEREAS, Company will provide a pharmaceutical agent(s) for the Study (an “Agent” as defined below), in return for
access to certain data arising from the Study as described in more detail in this Agreement. 
 NOW, THEREFORE, in consideration of
the foregoing and the mutual covenants and promises set forth herein and other good and valuable consideration, the receipt and adequacy which are hereby acknowledged, the Parties agree as follows: 

 

	1.	 DEFINITIONS 

1.1.    “Agent” shall mean the pharmaceutical agent(s) to be provided to QLHC by Company in order for
QLHC, CRO, and Institutions to conduct the Study, as listed on Exhibit B. 
 1.2.    “Agent-Related IP”
shall mean any Study Technology (other than Biomarker IP) that is owned or licensed to QLHC and sub-licensable by QLHC to Company in accordance with Section 3.3 of this Agreement, and that is directed specifically to a novel combination
regimen, new indication, or use relating to the Agent. 
 1.3.    “Background Technology” shall have
the meaning provided in Section 3.1. 
 1.4.    “Biomarker IP” shall mean any Study Technology
that is owned or licensed to QLHC and sub-licensable by QLHC to Company in accordance with Section 3.3 of this Agreement, and that is directed specifically to biomarkers that are relevant to the Agent. 

  
 1 

 1.5.    “Confidential Information” shall have the
meaning provided in Section 5.1. 
 1.6.    “CRO” shall have the meaning set forth in the recitals
to this Agreement. 
 1.7.    “Data Guidelines” shall have the meaning provided in Section 2.3.

 1.8.    “Disclosing Party” shall have the meaning provided in Section 5.1. 

1.9.    “Institution” shall mean any of the study sites that will administer and conduct the Study. 

1.10.    “Option” shall have the meaning provided in Section 3.3(b). 

1.11.    “Protocol” shall have the meaning set forth in the recitals to this Agreement. 

1.12.    “Recipient” shall have the meaning provided in Section 5.1. 

1.13.    “Specimens” shall have the meaning provided in Section 3.4. 

1.14.    “Study” shall have the meaning set forth in the recitals to this Agreement. 

1.15.    “Study Data” shall mean all information discovered or generated by QLHC or by Institutions in
the course and as a result of the Study. 
 1.16.    “Study Technology” shall have the meaning provided
in Section 3.2. 
  

	2.	 RESEARCH AND EVALUATION RESPONSIBILITIES 

2.1.    Agent(s). Promptly following the Effective Date, Company shall supply to QLHC or the Institution(s) the
Agent(s) in the quantities specified in the Protocol. Title to and ownership rights in the Agent(s) shall remain at all times with Company. The Parties understand and agree that delivery of the Agent(s) to QLHC or Institution(s) shall not convey any
ownership interest therein to QLHC or Institution(s), notwithstanding the use of such Agent(s) by QLHC or Institution(s) in conducting the Study. Company shall provide QLHC and Institution(s) any material information known to it regarding the
safety, efficacy, recommended dosage or usage, recommended storage conditions, data regarding correlations with specific biomarkers, and known risks or contraindications, if any, with respect to the Agent(s). QLHC and Institutions will use the Agent
only as specified in the Protocol. QLHC agrees, and shall direct Institution(s), not to transfer any such Agent(s), or any portion thereof, to any individual or entity not working on the Study without the prior written consent of Company. Upon any
termination of this Agreement, QLHC or Institution(s) shall return to Company or, at Company’s request destroy, any remaining quantities of the Agent to Company, in either case at Company’s expense. 

2.2.    Study Protocol. The scope and nature of, as well as the instructions and timeline for, the Study is set
forth in the Protocol, which is attached hereto as Exhibit A and incorporated herein. Company shall have the opportunity to review and comment on portions of the Protocol that are relevant to the Agent(s), and Company shall be informed of any
amendments to the Protocol that are relevant to the Agent(s) and shall have the opportunity to review and comment 

  
 2 

 
on such amendments. QLHC shall consider Company’s comments in good faith. Any such amendments to the Protocol shall be incorporated by reference as part of Exhibit A. If Company objects to
any material change to the Protocol with respect to the Agent(s), Company shall have the right to terminate this Agreement, as set forth in Section 7.4(c). Notwithstanding anything to the contrary herein, as between the Parties, all final
decisions regarding the Protocol and the conduct of the Study shall be made by QLHC. QLHC reserves the right to remove any Agent(s) from the Study at any time. 

2.3.    Use of Study Data. Company shall have the unrestricted right to freely use all Study Data that it receives
hereunder in whatever manner it desires, subject to Section 6.1. The process and timing for disclosure of Study Data to Company are described in the Study Data Use and Publication Guidelines attached as Exhibit C (the “Data
Guidelines”). 
 2.4.    Mutual Obligations. Each Party shall use commercially reasonable efforts to
devote the resources necessary to perform its obligations under this Article 2 and shall be solely responsible for its own costs and expenses incurred thereby, subject to any payment obligations set forth herein. Each Party shall comply with all
applicable laws and regulations in carrying out its obligations under this Agreement, including the guidelines and rules promulgated by the United States Food and Drug Administration (“FDA”), Health Canada, the International Conference on
Harmonization (“ICH”), and Good Clinical Practice (“GCP”) guidelines. 
 2.5.    Data Protection;
Informed Consent. The Parties agree to abide by all applicable laws and regulations regarding subject confidentiality and data protection, including without limitation the Health Insurance Portability and Accountability Act (HIPAA) of 1996. QLHC
shall be responsible for ensuring that each principal investigator on behalf of its respective Institution obtain from each subject, prior to the subject’s participation in the Study, a signed informed consent in a form approved in writing or
electronically by the IRB/IEC, as applicable. 
 2.6.    Debarment and Exclusion. QLHC shall ensure that each
Institution certifies that it does not, and shall not at any time during the Study, contract with or retain any person who will be directly or indirectly performing services under the Study if such a person is debarred by the FDA under 21 U.S.C.
§ 335a(a) or disqualified as described in 21 C.F.R. §312.70 or is the subject of debarment or disqualification proceeding by the FDA or any other regulatory authorities. QLHC will notify Company promptly if QLHC learns that either of these
certifications needs to be amended in light of new information. 
 2.7.    Adverse Experiences. The Protocol sets
forth the procedures regarding adverse reactions or side effects with respect to the Agent(s), such as adverse event reporting and prescription event monitoring, to be conducted by each Party in connection with the Study and this Agreement. 

2.8.    Payment and Payment Schedule. Company shall make payments to QLHC in accordance with Exhibit D attached
hereto and incorporated herein. 
  

	3.	 INTELLECTUAL PROPERTY 

3.1.    Background Technology; License to QLHC. As between the Parties, each Party will retain all right, title and
interest in any inventions, ideas, concepts, know-how, work product 

  
 3 

 
and other intellectual property (whether or not patentable) owned, controlled or exclusively licensed by such Party prior to the Effective Date or developed by such Party independent of the Study
(collectively, the “Background Technology”). Company hereby grants to QLHC a limited, non-exclusive, royalty-free, worldwide license to use any Background Technology for research purposes only in connection with the Study. Such
license shall be sub-licensable by QLHC solely to the CRO and each of the Institutions for research purposes only in connection with the Study. Additionally, Company hereby grants to QLHC a right of reference to all regulatory files and regulatory
approvals owned or controlled by Company that are filed with the FDA or other applicable regulatory authority and that relate to the Agent(s), solely to the extent necessary or useful for QLHC to perform the Study and/or obtain or maintain
regulatory approvals for the Study. 
 3.2.    Ownership of Inventions. Ownership of any and all inventions made
by one or both Parties, or by CRO, Institutions, or any other Study participants, in the course of the performance of the Study and any intellectual property related thereto (collectively, the “Study Technology”) shall be determined
by inventorship in accordance with U.S. patent laws. As a result, any and all Study Technology made solely by a Party or its employees or consultants shall be owned solely by such Party, and any and all Study Technology made jointly by, on the one
hand, a Party or its employees or consultants and, on the other hand, the other Party or its employees or consultants shall be owned jointly by the Parties. For clarity, ownership of Study Technology is subject to the ownership provisions regarding
Study Data, as set forth in Section 2.3. Notwithstanding anything to the contrary herein, Company shall retain all right, title and interest to the Agent(s), and, as between the Parties, QLHC shall retain all right, title and interest to the Study
Data. 
 3.3.    Licenses to Company. 

(a)    QLHC hereby grants to Company (i) a non-exclusive,
royalty-free, fully paid up, worldwide license, under the Agent-Related IP, to use and practice any and all Agent-Related IP solely in connection with the Agent(s), and (ii) an exclusive option (the “Agent IP Option”) to
negotiate a royalty-bearing, worldwide, sub-licensable, exclusive license, under the Agent-Related IP, to use and practice any and all Agent-Related IP solely in connection with the Agent(s). For clarity, no rights are granted under the
Agent-Related IP with respect to any molecule or product other than the Agent(s). 

(b)    QLHC hereby grants to Company (i) a non-exclusive, royalty-free,
fully paid up, worldwide license, under the Biomarker IP, to use and practice any and all Biomarker IP for internal, non-commercial research purposes only; and (ii) an exclusive option (collectively, the “Biomarker IP Option”,
and each of the Agent IP Option and Biomarker IP Option may be referred to herein as an “Option”) to negotiate a royalty-bearing, worldwide, sub-licensable license, under the Biomarker IP, to use and practice any and all Biomarker
IP solely in connection with the Agent(s), it being understood that such license shall be exclusive or non-exclusive (at Company’s election). 

(c)    Company shall indicate its intention to exercise any Option with respect
to any Agent-Related IP or Biomarker IP by notifying QLHC in writing within one (1) year after the completion of the Study. If Company so exercises such Option, the Parties shall negotiate in good faith the terms of such license during the
ninety (90) days following the date the Option is exercised, or for such longer time period as the Parties may agree. 

  
 4 

 (d)    Company acknowledges
and agrees that some or all of such Agent-Related IP and/or such Biomarker IP may be developed by one or more Institutions or other third parties, and that as a result (i) QLHC’s rights with respect to the Agent-Related IP and/or such
Biomarker IP may consist of license rights or rights under an exclusive option, and (ii) an Institution or other third party may hold the first or sole right to prosecute, maintain, enforce, and/or defend patents and patent application therein.

 (e)        Company acknowledges and agrees that QLHC
lacks sufficient financial and personnel resources to conduct, or to reimburse Institution(s) for conducting, prosecution and maintenance of the patents and patent applications in the Agent-Related IP and Biomarker IP for any significant time
period.     As a result, unless Company agrees to fund the costs of such prosecution and maintenance (either alone or together with others), QLHC shall have no obligation to initiate or continue such prosecution and maintenance.

 3.4.    Specimens. Any biological samples provided by or taken from any human subject in connection with
participating in a Study, including, but not limited to, blood samples, by- products and derivatives of any such samples (“Specimens”) shall be owned by QLHC. Company will have access to such Specimens in accordance with the Data
Guidelines. 
 3.5.    No Other Rights or Licenses. Except as otherwise expressly stated in this Agreement, no
express or implied right or license to any patent right or other intellectual property or proprietary information of either Party is granted by this Agreement. 
  

	4.	 REPRESENTATIONS AND WARRANTIES; LIMITATION OF LIABILITY 

4.1.    Representations and Warranties. Each Party hereby represents and warrants to the other Party that it has the
legal power, authority and right to enter into this Agreement and to perform its obligations hereunder, and that the execution, delivery and performance of this Agreement do not conflict with any agreement, instrument or understanding, oral or
written, to which such Party may be bound. 
 4.2.    Company Warranty. Company represents that any Agent(s)
delivered under the Agreement (a) was manufactured in accordance with cGMP and any applicable federal, state and local laws, rules and regulations and (b) complies at the time of delivery with the specifications for the Agent(s) (which
specifications shall be communicated to QLHC by Company prior to shipment of any Agent(s) to QLHC or an Institution hereunder). 

4.3.    No Infringement. Company represents and warrants that it has not received any written notice from a third
party alleging that the manufacture, use or sale of the Agent(s) infringes intellectual property rights of a third party. 

4.4.     Warranty Disclaimer. EXCEPT FOR THOSE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS
AGREEMENT, ANY AND ALL 

  
 5 

 
MATERIALS, SAMPLES, DATA AND INFORMATION PROVIDED HEREUNDER BY EITHER PARTY TO THE OTHER PARTY ARE PROVIDED “AS IS” WITHOUT ANY WARRANTIES OF ANY KIND, AND EACH PARTY EXPRESSLY
DISCLAIMS ALL WARRANTIES WITH RESPECT TO SUCH MATERIALS, SAMPLES AND INFORMATION, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

4.5.    Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, THAT THIS LIMITATION WILL NOT LIMIT OR RESTRICT (A) THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS UNDER ARTICLE 8, OR (B) DAMAGES AVAILABLE FOR BREACHES OF ARTICLE 5. 
  

	5.	 CONFIDENTIALITY 

5.1.    Confidentiality Obligations. For a period of ten (10) years from the Effective Date, each Party (the
“Recipient”) (i) shall keep confidential all information provided to it by the other Party (the “Disclosing Party”) pursuant to this Agreement (“Confidential Information”), (ii) shall not disclose to any
third party such Confidential Information except as permitted under this Agreement or otherwise authorized by the Disclosing Party, and (iii) shall use the Confidential Information of the Disclosing Party only for the purposes expressly
permitted by this Agreement. However, the foregoing obligations shall not apply to information that the Recipient can show based on competent evidence: 

(a)    was properly in the possession of the Recipient, without any restriction on use or disclosure,
prior to receipt from the Disclosing Party, or 
 (b)    is in the public domain at the time it is
disclosed to the Recipient or, after such disclosure, enters the public domain other than as a result of the Recipient’s breach of its obligations under this Article 5, or 

(c)    is properly obtained for use or disclosure by the Recipient from a third party who has the
right to disclose same and who is under no direct or indirect confidentiality obligation to the Disclosing Party with respect to such information, or 

(d)    is independently developed by or on behalf of the Recipient without the assistance of the
confidential information of the Disclosing Party by employees or consultants of the Recipient who did not have access to such confidential information. 

Confidential Information of the Disclosing Party may be disclosed by the Recipient to employees, agents or consultants of the Recipient, but only to the
extent required to accomplish the purposes of this Agreement and only if the Recipient obtains prior written agreement from the Recipient’s employees, agents and consultants to whom disclosure is to be made to hold in confidence and not make
use of such information for any purpose other than those permitted by this Agreement. The Recipient shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that such employees,
agents and consultants do not disclose or 

  
 6 

 
make unauthorized use of the Disclosing Party’s Confidential Information. In addition and notwithstanding anything to the contrary herein, QLHC shall be permitted to disclose to each
Institution or other Study participant any Confidential Information of Company that relates to the Agent(s) and is relevant to the conduct of the Study, provided that QLHC uses reasonable efforts to impose upon each such Institution or other
participant non-disclosure and non-use obligations that are substantially similar to those set forth herein. 

5.2.    Disclosure as Required by Law. Notwithstanding any provision of Section 5.1, the Recipient shall be
permitted to disclose the Disclosing Party’s Confidential Information solely to the extent that such disclosure is required by law or by order of any court or required or requested by any governmental authority (including without limitation the
FDA), provided, however, that the Recipient shall first have given advance notice to the Disclosing Party so as to permit the Disclosing Party to attempt to obtain a protective order requiring that the Confidential Information so disclosed be used
only for the purposes for which the order was issued or for such other legal requirement, and that the Recipient cooperates with the Disclosing Party in such efforts. 

5.3.    Copies. The Recipient agrees to return all copies and the original of any such Confidential Information
upon the request of the Disclosing Party, except that the Recipient may retain one (1) archival copy of such Confidential Information for the sole purpose of determining its obligations hereunder. 

 

	6.	 PUBLICATION AND PUBLICITY 

6.1.    Publication. QLHC intends to oversee and coordinate an effort to publish certain data resulting from the
Study (i.e., across all centers or institutions that participate in the Study), and such publication shall be governed by the Data Guidelines. Company shall have the right to publish or otherwise make public any data resulting from the Study under
this Agreement in accordance with the Data Guidelines. 
 6.2.    Agent-Related Research Communications. With
respect to any Primary I-SPY COVID-19 TRIAL Research Communication (as defined in the Data Guidelines) or Extended I-SPY COVID-19 TRIAL Research Communications (as defined in the Data Guidelines), in each case that discloses Study Data relating to
the Agent(s), QLHC will provide Company with an opportunity to review and comment on the portion of such Primary I-SPY COVID-19 TRIAL Research Communication or Extended I-SPY COVID-19 TRIAL Research Communication that relates to the Agent, on the
following schedule: (a) in the case of a Primary I-SPY COVID-19 TRIAL Research Communication or Extended I-SPY COVID-19 TRIAL Research Communication that is an abstract, at least three (3) days prior to the date of submission for
publication; (b) in the case of a Primary I-SPY COVID-19 TRIAL Research Communication that is a manuscript, at least thirty (30) days prior to the date of submission for publication; and (c) in the case of an Extended I-SPY COVID-19
TRIAL Research Communication that is a manuscript, at least fifteen (15) days prior to the date of submission for publication. In regards to Extended I-SPY COVID-19 TRIAL Research Communications, QLHC’s obligations under this section shall
only apply to those Extended I-SPY COVID-19 TRIAL Research Communications that disclose Study Data relating to the Agent(s) and that QLHC receives from members of the I-SPY COVID-19 TRIAL Research Community (as defined in the Data Guidelines) in
accordance with the timelines set forth in the Data Guidelines. QLHC will not be liable to Company in the event that 

  
 7 

 
I SPY COVID-19 TRIAL Research Community investigators neglect or refuse to provide such Extended I-SPY COVID-19 TRIAL Research Communications as described in the Data Guidelines. QLHC shall
consider any such comments made by Company in good faith. QLHC agrees and shall require each Institution and principal investigator to agree to delete, at Company’s written request, Company Confidential Information from any Primary I-SPY
COVID-19 TRIAL Research Communication. 
 6.3.    Publicity. Except for any disclosures required by applicable
laws or regulations, all announcements or publicity concerning the Study, the use of the Agent(s) in the Study, or this Agreement by Company must be approved in advance by QLHC, such approval not to be unreasonably withheld. Except for any
disclosures required by applicable laws or regulations, all announcements or publicity that mentions the Agent(s) or uses the name of the Company must be approved in advance by the Company, such approval not to be unreasonably withheld. The
foregoing shall not preclude publication or dissemination of the Study Data pursuant to the procedures set forth in the Data Guidelines. 
  

	7.	 TERM AND TERMINATION 

7.1.    Term. This Agreement shall commence as of the Effective Date, unless earlier terminated under this Article 7
or by written agreement of the Parties and shall expire upon the completion of the Study arm and release of final efficacy data to the public. Termination or expiration of this Agreement shall not affect any rights or obligations that accrued prior
thereto or in connection therewith. 
 7.2.    Termination for Material Breach. Either Party may terminate this
Agreement if the other Party materially breaches this Agreement and such breaching Party fails to cure the breach within thirty (30) days after receipt of written notice from the non-breaching Party, such notice specifying in detail the nature
of the breach. 
 7.3.    Termination by QLHC. QLHC may terminate this Agreement at any time upon giving thirty
(30) days advance written notice to Company. 
 7.4.    Termination by Company. Company may terminate this
Agreement (a) upon termination of the Study by QLHC, FDA or any other governmental or regulatory authority, or (b) if there exists a regulatory action or safety-related issue that makes continued use of the Agent(s) in the Study
impossible, illegal, or unethical, or (c) Company objects to any material change to the Protocol following the Effective Date with respect to the Agent(s). Any termination by Company for the foregoing reasons shall be effective immediately upon
written notice to QLHC. 
 7.5.    Effect of Termination. Following any termination of the Study with respect to
the Agent(s), QLHC will account for and return to Company or, at Company’s request, destroy, any remaining unused Agent(s) then existing at each Institution; in either case, at Company’s expense. Termination or expiration of this Agreement
for any reason shall not release either Party from any liability or obligation that already has accrued prior to such expiration or termination (including any milestone or other payment that has been triggered by an event occurring prior to the
effective date of termination or expiration). As soon as reasonably practicable following any termination or expiration of this Agreement, QLHC will provide Company with a final invoice detailing any outstanding payments, which invoice shall be due
upon receipt. 

  
 8 

 7.6.    Survival. Sections 2.3, 4.5, 7.5, 7.6, 8.2, 8.3 and 8.4
and Articles 3, 5, 6 and 9 shall survive the expiration or termination of this Agreement. 
  

	8.	 FOLLOW-ON CONFIRMATORY ARM 

8.1.    Amendment to CTPA. In the event that the graduating Agent is deemed by both Parties to be effective and
worthy of future study, the Parties agree to negotiate in good faith an Amendment to this CTPA for a Follow-On Confirmatory Arm. This Amendment will include terms and a payment schedule to be determined by QLHC as a subsequent Exhibit to this
Agreement. 
  

	9.	 INSURANCE AND INDEMNIFICATION 

9.1.    Insurance. QLHC represents that it shall maintain in full force and effect during the term of this Agreement
clinical trial liability insurance, comprehensive general liability insurance including broad contractual liability coverage, statutory worker’s compensation and employer’s liability; in each case comparable to that maintained by other
institutions engaged in clinical research. Company warrants that it maintains a policy or program of insurance or self-insurance at levels sufficient to support the indemnification obligations assumed under Section 8.2 below. 

9.2.    Indemnification by Company. Company agrees to indemnify, defend, and hold harmless each Institution, and
each Institution’s trustees, directors, officers, faculty, employees, students, and agents (including the Study investigators) (the “Institution Indemnitees”) and QLHC, CRO, and their respective directors, officers, employees,
and agents (including those individuals who participate in the management of the Study) (“QLHC Indemnitees”) from and against any and all costs, expenses, liabilities, damages, losses and harm (including reasonable legal expenses
and attorney’s fees) (collectively “Losses”) arising out of or resulting from any third party suits, claims, actions or demands (collectively, “Claims”) to the extent resulting from or caused by: (a) the
negligence, recklessness or willful misconduct of Company or its officers, directors, employees, or agents, (b) Company’s breach of its obligations, covenants, representations, or warranties under this Agreement, or (c) bodily injury
to a Study subject that is sustained as a direct result of the Agent(s) that is/are administered in the course of the Study in strict accordance with the Protocol, except in each case to the extent that a Claim or Loss arises out of or results from
the negligence, recklessness or willful misconduct of any of the Institution Indemnitees, QLHC Indemnitees, or QLHC’s breach of its obligations, covenants, representations, or warranties under this Agreement, or the Protocol design. 

As between the Parties, Company agrees that Company shall have primary liability for all Losses and Claims falling within the scope of the indemnification
obligation set forth in this Section 8.2, notwithstanding any indemnification obligations that QLHC may have with respect to such Losses or Claims under a separate agreement with any Institution. To the extent that an Institution provides an
indemnity in favor of QLHC, QLHC will request that such Institution provide to Company an indemnity of equivalent scope. 

  
 9 

 9.3.    General Conditions of Indemnification. Company’s
agreement to indemnify, defend and hold the QLHC Indemnitees and the Institution Indemnitees harmless is conditioned on QLHC (in the case of the QLHC Indemnitees) or Institution (in the case of the Institution Indemnitees) (a) providing written
notice to Company of any Loss or Claim arising out of the indemnified activities within thirty (30) days after the indemnified Party has knowledge of such Loss or Claim, provided however that failure or delay in providing such notice shall not
relieve Company of its indemnification obligation except to the extent it is prejudiced thereby; (b) permitting the indemnifying Party to assume full responsibility to investigate, prepare for and defend against any such Claim;
(c) assisting the Company, at Company’s reasonable expense, in the investigation of, preparation for and defense of any Claim; and (d) not compromising or settling such Claim without Company’s written consent. 

9.4.    Third Party Beneficiary. Each Institution is an intended third-party beneficiary of the terms of this
Article 8 and shall have the right to enforce such terms against Company in such Institution’s own name. 
  

	10.	 MISCELLANEOUS 

10.1.    Independent Contractors. The Parties shall perform their obligations under this Agreement as independent
contractors and nothing contained in this Agreement shall be construed to be inconsistent with such relationship or status. Neither Party has the authority to bind or act on behalf of the other Party. This Agreement shall not constitute, create or
in any way be interpreted as a joint venture or partnership of any kind. 
 10.2.    Entire Agreement. This
Agreement, including all Exhibits hereto, sets forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter of this Agreement, and supersedes and
terminates all prior agreements, negotiation and understandings between the Parties, whether oral or written, with respect to such subject matter, and there are no covenants, promises, agreements, warranties, representations, conditions or
understandings, either oral or written, between the Parties hereto with respect to such subject matter other than as set forth herein. No subsequent alteration, modification, amendment, change or addition to this Agreement shall be binding upon the
Parties unless reduced to writing and signed by the respective authorized officers of the Parties. In the event of any conflict between the terms and conditions of this Agreement and those in the Exhibits hereto, the terms and conditions of this
Agreement shall control. 
 10.3.    Governing Law. This Agreement shall be governed and interpreted in
accordance with the laws of the State of California, U.S.A., without regard to any conflicts of law rules that would provide for the application of the laws of another jurisdiction. The Parties agree that any claim or controversy arising out of or
relating to this Agreement or any breach hereof shall be submitted to a court of applicable jurisdiction in the State of California and each Party hereby consents to the jurisdiction and venue of such court. 

10.4.    Severability. In case any one or more of the provisions contained in this Agreement shall, for any reason,
be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been 

  
 10 

 
contained herein. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or
subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

10.5.    Assignment. This Agreement and any rights and obligations contained herein shall not be assigned by either
Party without the prior written consent of the other Party, such consent not to be unreasonably withheld, and any attempted assignment in violation of this Section 9.5 shall be void and of no force and effect, except that each Party shall have
the right to assign this Agreement without the other Party’s consent in connection with a merger, acquisition or sale of substantially all of the assets relating to the subject matter hereof. The Parties’ rights and obligations hereunder
will bind and inure to the benefit of their respective successors, heirs, executors and administrators and permitted assigns. 

10.6.    Waiver. The failure of either Party to enforce, at any time, or for any period of time, the provisions
hereof will not be construed as a waiver of such provision and will in no way affect that Party’s right to enforce such provisions. No waiver of any of the provisions of this Agreement shall be effective unless such waiver is in writing and
signed by the authorized representative of the Party to be charged therewith, and no waiver of any provision hereof will be deemed a waiver of any subsequent breach of the same or any other provisions of this Agreement. 

10.7.    Force Majeure. Any delays in performance of any of the duties or obligations by a Party under this
Agreement shall not be considered a breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the Party affected, including but not limited to acts of God, embargoes, governmental restrictions, strikes or
other concerted acts of workers, fire, earthquake, flood, explosion, riots, wars, civil disorder, rebellion or sabotage. The Party suffering such occurrence shall immediately notify the other Party as soon as practicable and any time for performance
hereunder shall be extended by the actual time of delay caused by the occurrence, provided that the Party affected by such event uses reasonable efforts to overcome such delay. 

10.8.    Headings. The headings herein are for the purpose of convenience of reference only and are not intended to
define or limit the contents of this Agreement. 
 10.9.    Ambiguities. Ambiguities, if any, in this Agreement
shall not be construed against either Party, regardless of which Party is deemed to have authored such provision. 

10.10.    Notices. Any notices required or permitted hereunder shall be given to the appropriate Party at the
address specified below or at such other address as the Party shall specify in writing. Such notice shall be deemed given upon receipt when given by personal delivery, facsimile or overnight courier service, or five (5) days after the date of
mailing when sent by certified or registered mail, postage prepaid, properly addressed as follows: 
 If to QLHC: 

Quantum Leap Health Care Collaborative 

3450 California Street, 2nd Floor 

San Francisco, CA 94118 

  
 11 

			
	Email: contracts@quantumleaphealth.org with copy to finance@quantumleaphealth.org
	Tel. (855) 866-0505 ext. 101
		
	If to Company:	  	
	Company name	  	NeuroRx, Inc.
	Address	  	1201 North Market Street, Wilmington, DE 19801
	Attn:	  	Brian Del Buono
	Email:	  	bdelbuono@neurorxpharma.com cc jjavitt@neurorxpharma.com
	Tel.	  	2023401352

 10.11.    Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall be deemed to be an original document, but all such separate counterparts shall constitute only one and the same Agreement. 

10.12.    Injunctive Relief. Each Party acknowledges and agrees that any breach of this Agreement by such Party
will cause irreparable damage to the other Party and that in the event of such breach, the non-breaching Party shall have, in addition to any and all remedies of law, the right to injunction, specific performance or other equitable relief to prevent
the violation of the breaching Party’s obligations hereunder. 
 << Signature Page Follows >> 

  
 12 

 IN WITNESS WHEREOF, the Parties have executed this
Clinical Trial Participation Agreement as of the Effective Date. 
  

									
	QUANTUM LEAP HEALTH CARE COLLABORATIVE	 		 	NeuroRx, Inc.
					
	Signed:	 	 /s/ James Palazzolo
	 		 	Signed:	 	 /s/ Jonathan C. Javitt

	Name:	 	James Palazzolo	 		 	Name:	 	Jonathan C. Javitt, MD, MPH
	Title:	 	CEO	 		 	Title:	 	CEO
	Date:	 	12/29/2020	 		 	Date:	 	12/29/2020

  
 13 

 EXHIBIT A 

PROTOCOL APPENDIX 
 PROTOCOL APPENDIX
INCLUDED AS A SEPARATE DOCUMENT AND CONSIDERED INCORPORATED HEREIN. 

  
 14 

 EXHIBIT B 

AGENT 
 AGENT NAME: RLF-100 (Aviptadil)

 Company will provide Agent(s) and arrange for the distribution of Agent(s) through its contracted drug distributor to up to 26 institutions in the
United States. Projected accrual is approximately 120 subjects receiving the Agent(s) per regimen. 

  
 15 

 EXHIBIT C 

STUDY DATA USE AND PUBLICATION GUIDELINES 

STUDY DATA USE AND PUBLICATION GUIDELINES ARE INCLUDED AS A SEPARATE DOCUMENT AND CONSIDERED INCORPORATED HEREIN 

  
 16 

 EXHIBIT D 

PAYMENT 
 This Exhibit is made a part of
and is incorporated into the Clinical Trial Participation Agreement (the “Agreement”) and sets forth the terms under which NeuroRx, Inc. (“Company”) will provide funding in support of the clinical trial
protocol titled “I-SPY COVID-19 TRIAL: An Adaptive COVID-19 Trial Design in the Setting of Critically Ill Patients” (“Study”), a public-private partnership sponsored by Quantum Leap Health Care Collaborative
(“QLHC”), a California 501(c)(3) charitable foundation. Company is providing funding with the understanding that the funds are to be used for scientific purposes and not for the purpose of promoting or marketing any products.

 1. Payments: 
 [***] 

  
 17Exhibit
10.1

 

EXCHANGE
AGREEMENT

 

THIS
EXCHANGE AGREEMENT (the “Agreement”), dated as of May 12, 2021, is made by and between Alset EHome International Inc., a
Delaware corporation (“Company”), and the holder of a $28,363,966 convertible note, issued on March 12, 2021, which is convertible
into shares of common stock, $0.001 par value per share of the Company (the “Note”), signatory hereto (each a “Holder”).

 

WHEREAS,
the Holder desires to exchange $13,000,000 in principal
under the Note by exchanging such amount under the Note as set forth on Schedule A;

 

WHEREAS,
the Company has authorized a new series of convertible preferred stock of the Company designated as Series B Convertible Preferred Stock,
$0.001 par value, the terms of which are set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series
B Convertible Preferred Stock (the “Certificate of Designations”) in the form attached hereto as Exhibit A (together
with any convertible preferred shares issued in replacement thereof in accordance with the terms thereof, the “Preferred Stock”),
which Preferred Stock shall be convertible into the Company’s Common Stock, in accordance with the terms of the Certificate of
Designations;

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended
(the “Securities Act”), the Company desires to exchange with the Holder, and the Holder desires to exchange with the Company,
$13,000,000 in principal under Note for shares of the Company’s Preferred Stock.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and Holder agree as follows:

 

1.
Terms of the Exchange. The Company and Holder agree that the Holder will exchange $13,000,000 in principal under the Note (the
“Portion of the Note”) (and will relinquish any and all other rights he may have under the Portion of the Note in exchange
for such number of shares of Preferred Stock (the “Preferred Shares”, and such
Preferred Shares as converted into Common Stock, the “Conversion Shares”, and together with the Common Shares and the Preferred
Shares, the “Securities”) as set forth on Schedule A, annexed hereto.

 

2.
Closing. Upon satisfaction of the conditions set forth herein, a closing shall occur at the principal offices of the Company,
or such other location as the parties shall mutually agree. At closing, Holder shall deliver the Portion of the Note to the Company pursuant
to this Agreement and the Company shall deliver to such Holder a certificate evidencing the Preferred
Shares, in the name(s) and amount(s) as indicated on Schedule A annexed hereto. Upon closing, the Portion of the Note shall
be cancelled and Holder will have no remaining rights, powers, privileges, remedies or interests under the Portion of the Note.

 

3.
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

4.
Representations and Warranties of the Holder. The Holder represents and warrants as of the date hereof and as of the closing to
the Company as follows:

 

    	 

     

    

 

a.
Authorization; Enforcement. The Holder
has the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to
carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Holder and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Holder and
no further action is required by the Holder. This Agreement has been (or upon delivery will have been) duly executed by the Holder and,
when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Holder enforceable against
the Holder in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar
as indemnification and contribution provisions may be limited by applicable law.

 

b.
Information Regarding Holder. Holder is
an “accredited investor”, as such term is defined in Rule 501 of Regulation D promulgated by the United States Securities
and Exchange Commission (the “Commission”) under the Securities Act, is experienced in investments and business matters,
has made investments of a speculative nature and has purchased securities of companies in private placements in the past and, with its
representatives, has such knowledge and experience in financial, tax and other business matters as to enable the Holder to utilize the
information made available by the Company to evaluate the merits and risks of and to make an informed investment decision with respect
to the proposed purchase, which represents a speculative investment. Holder has the authority and is duly and legally qualified to purchase
and own the Securities. Holder is able to bear the risk of such investment for an indefinite period and to afford a complete loss thereof.

 

c.
Legend. The Holder understands that the
Securities have been issued (or will be issued in the case of the Conversion Shares) pursuant to an exemption from registration or qualification
under the Securities Act and applicable state securities laws, and except as set forth below, the Securities shall bear any legend as
required by the “blue sky” laws of any state and a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of such stock certificates):

 

[NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE
HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A)
AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO
THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAIDACT
OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.
NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTIONWITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING
ARRANGEMENT SECURED BY THE SECURITIES.

 

    	 

     

    

 

d.
Restricted Securities. The Holder understands
that: (i) the Securities have not been and are not being registered under the Securities Act or any state securities laws, and may not
be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) the Holder shall have delivered
to the Company (if requested by the Company) an opinion of counsel to the Holder, in a form reasonably acceptable to the Company, to
the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from
such registration, or (C) the Holder provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred
pursuant to Rule 144 or Rule 144A promulgated under the Securities Act (or a successor rule thereto) (collectively, “Rule 144”);
(ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further,
if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale
is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption
under the Securities Act or the rules and regulations of the SEC promulgated thereunder; and (iii) neither the Company nor any other
Person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the
terms and conditions of any exemption thereunder.

 

5.
Representations and Warranties of the Company. The Company hereby makes the
following representations and warranties to the Holder:

 

a.
Authorization; Enforcement. The Company
has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement
and each of the other agreements entered into by the parties hereto in connection with the transactions contemplated by this Agreement
(collectively, the “Exchange Documents”) and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and
no further action is required by the Company, the Board of Directors of the Company or the
Company’s stockholders in connection therewith, including, without limitation, the issuance of the Preferred Shares, and the reservation
for issuance and issuance of Conversion Shares issuable upon conversion of the Preferred Shares have been duly authorized by the Company’s
Board of Directors and no further filing, consent, or authorization is required by the Company, its Board of Directors or its stockholders,
other than the approval by the Company’s shareholders to increase the Company’s authorized Common Stock. This Agreement and
any Other Agreement (as defined herein) have been (or upon delivery will have been) duly executed by the Company and, when delivered
in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company
in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

b.
Organization and Qualification. Each of
the Company and its subsidiaries (the “Subsidiaries”) are entities duly organized
and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and
authorization to own their properties and to carry on their business as now being conducted and as presently proposed to be conducted.
Each of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every
jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used in
this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business, properties, assets, liabilities,
operations (including results thereof), condition (financial or otherwise) or prospects of the Company or any Subsidiary, individually
or taken as a whole, (ii) the transactions contemplated hereby or in any of the other Exchange Documents or (iii) the authority or ability
of the Company to perform any of its obligations under any of the Exchange Documents.

 

    	 

     

    

 

c.
No Conflict. The execution, delivery and performance
of the Exchange Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including, without limitation, the issuance of the Preferred Shares and reservation for issuance and
issuance of the Conversion Shares) will not (i) (i) result in a violation of the Certificate of Incorporation (as defined below) or other
organizational documents of the Company or any of its Subsidiaries, any capital stock of the Company or any of its Subsidiaries or Bylaws
(as defined below) of the Company or any of its Subsidiaries, (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is
a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state
securities laws and regulations and the rules and regulations of the Nasdaq Stock Market (the “Principal Market”) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected
except, in the case of clause (ii) or (iii) above, to the extent such violations that could
not reasonably be expected to have a Material Adverse Effect.

 

d.
No Consents. Neither the Company nor any Subsidiary
is required to obtain any consent from, authorization or order of, or make any filing or registration with, any court, governmental agency
or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its respective
obligations under or contemplated by the Exchange Documents, in each case, in accordance
with the terms hereof or thereof, except as previously obtained. All consents, authorizations,
orders, filings and registrations which the Company or any Subsidiary is required to obtain pursuant to the preceding sentence have been
obtained or effected on or prior to the date of this Agreement, and neither the Company nor any of its Subsidiaries is aware of any facts
or circumstances which might prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registration, application
or filings contemplated by the Exchange Documents.

 

e.
Securities Law Exemptions. Assuming the accuracy
of the representations and warranties of the Holder contained herein, the offer and issuance by the Company of the Securities is exempt
from registration under the Securities Act. The offer and issuance of the Securities is exempt from registration under the Securities
Act pursuant to the exemption provided by Section 3(a)(9) thereof. The Company covenants and represents to the Holder that neither the
Company nor any of its Subsidiaries has received, anticipates receiving, has any agreement
to receive or has been given any promise to receive any consideration from the Holder or any other Person in connection with the transactions
contemplated by the Exchange Documents.

 

f.
Issuance of Securities. The issuance of the Preferred
Shares are duly authorized and upon issuance in accordance with the terms of the Exchange
Documents shall be validly issued, fully paid and non-assessable and free from all taxes,
liens, charges and other encumbrances with respect to the issue thereof. Upon issuance or conversion in accordance with the Certificate
of Designations, the Conversion Shares, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive
or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with the holders being entitled to
all rights accorded to a holder of Common Stock.

 

6.
Miscellaneous.

 

a.
Successors and Assigns. This Agreement
shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.

 

    	 

     

    

 

b.
Governing Law. This Agreement shall be governed
by and construed under the laws of the State of Delaware without regard to the choice of law principles thereof.

 

c.
Severability. If any provision of this Agreement
shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability
of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction.

 

d.
Counterparts/Execution. This Agreement may be
executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party. In the event that any signature is delivered by facsimile
transmission or by an e-mail which contains an electronic file of an executed signature page, such signature page shall create a valid
and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such
facsimile or electronic file signature page (as the case may be) were an original thereof.

 

e.
Entire Agreement; Amendments. This Agreement
constitutes the entire agreement between the parties with regard to the subject matter hereof and thereof, superseding all prior agreements
or understandings, whether written or oral, between or among the parties. This Agreement may be amended, modified, superseded, cancelled,
renewed or extended, and the terms and conditions hereof maybe waived, only by a written instrument signed by all parties, or, in the
case of a waiver, by the party waiving compliance. Except as expressly stated herein, no delay on the part of any party in exercising
any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party of any right,
power or privilege hereunder preclude any other or future exercise of any other right, power or privilege hereunder.

 

f.
Headings. The headings used in this Agreement
are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

(Signature
Pages Follow)

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed as of the day and year first above written.

 

	ALSET
    EHOME INTERNATIONAL INC.	 
	 	                     	 
	By:	/s/
    Rongguo Wei	 
	Name:	Rongguo
Wei	 
	Title:	Co-Chief
    Financial Officer	 

 

	HOLDER:	 
	 	 	 
	By:
    	/s/
    Chan Heng Fai	 

 

    	 

     

    

 

SCHEDULE
A

 

	Name of Holder	 	Number
                                                                                  of Shares of Preferred Stock to be Issued (Each share of Preferred Stock convertible into 1,000 shares of Common
                                                                                  Stock)
	 
	Chan Heng Fai	 	2,132

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]